The core application of Yacella is generally used to help with the prevention of pregnancy for females of reproductive potential. It is also used for its therapeutic applications in women who choose to use an oral contraceptive for these purposes.

---

The medication is commonly used across conditions presenting with episodic or fluctuating symptom patterns. It is relevant for easing Premenstrual Dysphoric Disorder (PMDD) symptoms, managing Moderate Acne Vulgaris in women desiring contraception, and assisting with cycle regularity and the severity of pain related to dysmenorrhea. This therapy helps address symptom clusters that create noticeable functional strain, including severe mood swings, pronounced anxiety, physical bloating, and inflammatory skin lesions. The support provided may help patients cope more steadily with these difficult, recurrent episodes.

---

Quick Facts: Therapeutic Uses

Focus Area	Benefit Provided
Reproductive Management	Assists with cycle regularity and is commonly used to help with the prevention of pregnancy.
Symptom Relief (PMDD)	Provides support that helps ease the overall symptom burden related to severe mood and physical symptoms.
Dermatology Support	Plays a role in managing inflammatory and non-inflammatory skin manifestations in Moderate Acne Vulgaris.

Regulatory References

1. DailyMed overview of Drospirenone and Ethinyl Estradiol

Yacella is only indicated for use by females of reproductive potential who have reached menarche (the onset of menstruation) and is not intended for use in the post-menopausal population. Official regulatory labeling outlines several conditions and populations for whom use is contraindicated (must not be used).

Eligibility Classification	Prohibited Conditions (Examples)
Vascular/Thrombotic Risk	History of Venous or Arterial Thrombotic disease (e.g., DVT, Stroke, PE, MI), smoking and being over age 35, or uncontrolled hypertension.
Organ Function/Endocrine	Severe renal impairment, hepatic impairment (including liver tumors), or adrenal insufficiency is an absolute prohibition.
Hormone-Sensitive	Known or suspected hormone-sensitive malignancies (e.g., breast cancer), Migraine with aura, or undiagnosed vaginal bleeding.

Use is also contraindicated during pregnancy. For women who are breastfeeding, use is generally not recommended immediately postpartum as it may affect milk production. The medicine is also contraindicated if the patient is receiving certain combination drug therapies for Hepatitis C. Temporary discontinuation is required around major surgery or during prolonged immobilization.

Interactions with other medicines and products

Yacella's interaction profile is officially defined by regulatory restrictions and exposure-altering patterns. Contraindicated combinations include specific Hepatitis C Virus (HCV) drug regimens, such as those containing Ombitasvir, Paritaprevir/Ritonavir, with or without Dasabuvir, due to the risk of increased liver enzyme elevations. Oral Tranexamic Acid is also contraindicated because of a documented increase in thrombotic risk.

Pharmacokinetic interactions are governed by the CYP3A4 enzyme system. Co-administration with strong CYP3A4 inducers may decrease the plasma exposure of Yacella's active components, potentially reducing contraceptive effectiveness. Conversely, strong CYP3A4 inhibitors are documented to increase the systemic exposure of both Drospirenone and Ethinylestradiol.

A significant pharmacodynamic interaction relates to Drospirenone's anti-mineralocorticoid activity. Co-administration with other potassium-increasing agents (such as certain diuretics or ACE inhibitors) carries a documented risk of hyperkalemia, necessitating mandated serum potassium monitoring during the first treatment cycle. Furthermore, the product is contraindicated in females over 35 years of age who smoke and in patients with known hepatic or renal impairment, as Drospirenone exposure is officially documented to be significantly higher in these conditions.

Yacella, a combination of ethinylestradiol (estrogen) and drospirenone (progestin), exerts its effects through multiple pharmacodynamic actions targeting central and peripheral systems.

Gonadotropin Suppression and Follicular Control

The hormonal components act on the hypothalamic-pituitary-ovarian axis. Exogenous estrogen and progestin provide negative feedback to the pituitary gland, suppressing the release of Follicle-Stimulating Hormone (FSH) and Luteinizing Hormone (LH). This pathway modulation leads to the central inhibition of follicular development, thereby preventing the predicted LH surge.

Modulation of Cervical and Endometrial Systems

Drospirenone initiates structural changes within the reproductive tract. It modifies molecular steps in the cervical system, resulting in the thickening of cervical mucus, which hinders sperm motility and penetration. Concurrently, drospirenone alters the endometrial lining, causing specific tissue changes.

Anti-Mineralocorticoid Receptor Engagement

Drospirenone engages the mineralocorticoid receptor (MR) as an antagonist. This receptor-mediated signaling affects the renal tubules, influencing the handling of sodium and water, which contributes to the drug’s overall physiological effect profile.

Yacella is administered through the oral route as part of a precise 28-day cyclic regimen. The standard regimen requires taking one tablet once daily at approximately the same time every day to ensure consistent drug delivery.

---

Dosing and Schedule

The regimen consists of 24 active tablets (containing Drospirenone and Ethinylestradiol), followed by 4 inactive (placebo) tablets. Tablets must be ingested in the order directed by the sequence on the blister pack, and a new 28-day course must be initiated immediately after the previous one is completed. Standard instructions permit administration to begin using either a Day 1 Start (first day of the menstrual cycle) or a Sunday Start. Yacella may be taken with or without food, though it is recommended to be taken after the evening meal or at bedtime.

---

Procedural Conditions and Use Restrictions

For the initial seven consecutive days of administration, instructions require the use of a non-hormonal back-up method of contraception. The medicine is not indicated for use in females who have not yet achieved menarche. Furthermore, prescribing information states that Yacella should not be administered to patients with pre-existing renal or hepatic impairment. This adherence to sequence, timing, and specific health criteria defines the standardized approach to administration.

Research Evidence / Overview of Studies

Initial Investigations and Design

Initial research explored the potential mechanism of action. Phase I and II clinical trials focused primarily on characterizing the drug's initial profile and participant response. Research explored whether the drug influenced measures of inflammation and pain levels in a small group of participants.

• Phase I: Focused on identifying a tolerable dose range.
• Phase II: Explored various administration protocols, including starting doses at lower levels, and investigated the time to first observed response.

Study Findings in Chronic Conditions

Randomized Controlled Trials (RCTs)

A series of multi-center, double-blind RCTs examined participant responses in individuals with the target condition. Results were compared to placebo over a 12-week study period. The primary measurement for these studies was a pre-specified change in the validated symptom scale.

• Symptom Measures: Changes in symptom scores were noted among participants during the study periods.
• Quality of Life: Research investigated measures related to the quality of life, using standardized patient-reported outcome measures.

Long-term Observational Studies

Long-term observational research has tracked outcomes among participants who continued the study regimen for extended periods (up to one year). Findings were reported in multiple cohorts.

Tolerability and Safety Measures

Multiple studies evaluated the drug’s tolerability and participant responses. The most frequently reported adverse events (AEs) were mild to moderate gastrointestinal (GI) disturbances and headache. In studies, participants often reported resolution of these events.

• Hepatotoxicity: Liver enzyme levels were monitored closely across all phases. The current evidence base has limited data on long-term hepatotoxicity risks.
• Drug Interactions: Studies examined potential interactions with commonly co-prescribed medications.

The treatment was evaluated in studies investigating symptomatic conditions.

Key Studies & References

1. Oral Contraceptive Pills - StatPearls - NCBI Bookshelf

Common questions about Yacella (FAQ)

Q: How is Yacella different from other medicines used for the same condition?

A: Official labeling describes the active ingredient drospirenone as unique because it possesses mild anti-mineralocorticoid and antiandrogenic properties. This is a factual distinction between Yacella and other combined hormonal contraceptives that use different types of progestins.

Q: Can Yacella cause a change in my weight?

A: Regulatory information for products containing the active ingredients in Yacella has listed weight gain as a possible adverse reaction. This is documented as an occurrence, but individual experiences may vary.

Q: Is it common for people to feel tired when they first start taking Yacella?

A: Tiredness is one of the symptoms that has been reported in association with the use of the active ingredients in Yacella. As with any medication, individual experiences can vary, and a person's body may require an adjustment period.

Q: Does Yacella affect mood or cause emotional changes?

A: Official documentation lists Depressive Mood as a Common adverse reaction. Generally, the official safety label notes that other mood changes have also been reported.

Q: What should I do if a side effect seems to get worse over time?

A: Official labeling advises patients to notify their healthcare provider if any pre-existing conditions or risk factors aggravate (get worse) or first appear. This allows for a professional assessment regarding the continuation of use.

Q: What is the difference between an adverse reaction and a side effect?

A: In official regulatory documentation, both terms describe unwanted effects. Adverse Reactions (ARs) are formally defined and classified based on their frequency (e.g., Common, Rare) and the body system affected, based on established evidence from studies. They are used to help communicate documented risks.

Q: If I have kidney problems, can I still take Yacella?

A: Official regulatory information describes the medicine as contraindicated (must not be used) in patients with severe renal impairment (severe kidney problems) or adrenal insufficiency. This is because official data shows exposure to the active components is significantly higher in these conditions.

Q: Are there specific patient education resources from government agencies about Yacella?

A: Yes, governmental bodies like the FDA publish documents such as Drug Safety Communications and Patient Labeling about the medicine’s active ingredients. These resources are intended to officially inform the public about the product's benefits, risks, and proper use.

Q: What happens if I miss a dose of Yacella?

A: The official prescribing information includes protocols detailing actions based on when and how many active tablets are missed. These protocols often include information about the need for temporary backup non-hormonal contraception to help maintain contraceptive effectiveness.

Q: How long does it typically take to see any effect from Yacella?

A: Official prescribing information states that a patient's body requires at least 7 days to adjust before the medicine prevents pregnancy. For this reason, official information recommends the use of non-hormonal contraception during the first seven days of the first cycle.

Q: Are there any specific foods or drinks I should avoid while on Yacella?

A: Official documents note that Grapefruit and grapefruit juice may change the amount of the medicine's components that are absorbed by the body. Official documents are the source of information regarding any specific dietary warnings.

Q: Can Yacella affect the effectiveness of birth control pills?

A: Yacella is officially classified as a Combined Oral Contraceptive Pill (COC) itself, and its primary purpose is the prevention of pregnancy. It does not affect the effectiveness of other hormonal birth control pills because it is classified as the contraceptive medicine itself.

Q: What if I'm taking herbal supplements; can they interact with Yacella?

A: Official documentation warns that certain herbal products that induce the CYP3A4 enzyme, such as St. John's Wort, may decrease the plasma concentration of the active components, which may decrease contraceptive effectiveness.

Q: What does 'contraindicated' mean in the context of Yacella eligibility?

A: Contraindication is a term used in official medical documentation to describe a specific situation or pre-existing condition. It signifies that the medicine should not be used because its use may be harmful to the person.

Q: Can older adults use Yacella, or is it only for younger patients?

A: The medicine is not indicated for use in the post-menopausal population. Official guidelines generally consider combined oral contraceptives suitable for women until the typical age of natural menopause. Use is specifically contraindicated for women over 35 who smoke due to increased vascular risks.

Q: What happens when a person stops taking Yacella?

A: Discontinuation of the medicine is associated with the return of natural menstrual cycles and fertility. Official information notes that it may take a few months for the natural menstrual cycle to reestablish the specific pattern that existed before beginning the medicine.

Q: Why are people with certain pre-existing conditions not supposed to use Yacella?

A: The medicine is contraindicated in high-risk patients because official data shows that systemic exposure to the active components is significantly higher in groups with renal or hepatic impairment. Furthermore, due to drospirenone's anti-mineralocorticoid activity, use is prohibited in patients predisposed to hyperkalemia (high potassium).

Q: Does Yacella require special monitoring or blood tests?

A: Regulatory warnings indicate that serum potassium concentration monitoring is advised during the first cycle for patients also taking other potassium-increasing medications. Furthermore, official labeling states that prediabetic and diabetic women require monitoring while taking the medicine due to possible effects on metabolism.

Q: Is there a generic version of Yacella available?

A: Yes, the combination of active ingredients in Yacella (drospirenone and ethinyl estradiol) is available in FDA-approved generic equivalents. These generics meet the same high quality and efficacy standards as the original product.

Q: What is the typical time frame for side effects to appear after starting the medicine?

A: Official warnings state that the risk of serious adverse reactions, such as Venous Thromboembolism (VTE), is highest during the first year of use. Other common effects, such as nausea, are often mild and tend to occur within the first few days or weeks as the body adjusts to the hormones.

Q: What should I know about the risk of allergic reactions to Yacella?

A: Hypersensitivity (severe allergic reaction) is documented as a Rare adverse reaction in the official safety profile. Official labeling also includes a warning that the estrogen component may induce or exacerbate symptoms of hereditary angioedema (swelling).

Q: How is Yacella eliminated from the body?

A: The active components are rapidly absorbed and primarily eliminated from the body via metabolites (breakdown products) in both the urine and feces. This is the natural pharmacokinetic process described in official documentation.

Q: Can Yacella be used by people with diabetes?

A: Official labeling states that prediabetic and diabetic women require monitoring while taking the medicine due to possible effects on carbohydrate and lipid metabolism. Official guidance indicates that alternative methods of contraception may be considered for women with uncontrolled or poorly controlled diabetes mellitus.

Q: What are the main findings from the research on Yacella's efficacy?

A: Randomized Controlled Trials (RCTs) examined participant response over a 12-week period using a pre-specified change in a validated symptom scale as the primary measurement. The findings noted changes in symptom scores among participants during the study periods.

Storage and Handling Requirements

Yacella tablets must be stored at Controlled Room Temperature, typically maintained between 20 C and 25 C (68 F and 77 F).

The medication should be kept in its original blister packaging to protect it from light and moisture and to ensure stability until the expiration date. Avoid exposure to extreme temperatures, including freezing or excessive heat. For safety, Yacella must be stored out of the reach and sight of children.

Disposal Instructions

To safely dispose of expired or unused Yacella, do not flush the medicine down a toilet or throw it in household trash. Instead, dispose of the product through an approved Take-Back Program or pharmacy collection point, following local and federal regulations for pharmaceutical waste.